- Treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test
- In combination with trametinib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Coverage of drugs is first determined by the member’s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document.